SPRY

A securities class action lawsuit has been filed against ARS Pharmaceuticals for allegedly providing false and misleading statements regarding the timeline for expanded insurance coverage of its epinephrine nasal spray product 'neffy' through CVS Caremark. The company allegedly stated coverage would begin July 1, 2026, while concealing material adverse facts about the actual timeline, causing investors to purchase securities at artificially inflated prices. The lead plaintiff deadline is October 5, 2026.

A securities class action lawsuit has been filed against ARS Pharmaceuticals, Inc. (SPRY) for allegedly providing false and misleading statements regarding the timeline for expanded insurance coverage of its epinephrine nasal spray product 'neffy' through CVS Caremark. The company allegedly misled investors about expected July 1, 2026 coverage, causing shareholders to purchase securities at artificially inflated prices. The lead plaintiff deadline is October 5, 2026.

A class action lawsuit has been filed against ARS Pharmaceuticals for allegedly providing misleading statements about expanded insurance coverage for its epinephrine nasal spray product (neffy) with CVS Caremark. The company reportedly expressed confidence that coverage would begin July 1, 2026, while failing to adequately disclose risks that the deadline might not be met, potentially impacting summer and back-to-school sales.

Rosen Law Firm has filed securities class action lawsuits against Tigo Energy, Inc., AST SpaceMobile, Inc., and ARS Pharmaceuticals, Inc. The Tigo lawsuit alleges the company made materially false statements regarding revenue projections based on an EG4 partnership that would not materially contribute revenue until Q4 2026 at the earliest. Investors who purchased securities during the class periods may be eligible for compensation. Lead plaintiff deadlines vary by case.